Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers

M. Plebani, F. Navaglia, D. Basso, M. De Paoli, M. O. Nicoletto, E. Maraglino, G. C. Torre

Research output: Contribution to journalArticlepeer-review


UGP, the β-core fragment of human chorionic gonadotrophin, has been proposed as a tumor marker for gynecological malignancies. This fragment may be detected in a single morning-specimen of urine using an enzyme immunoassay. In this study, the diagnostic usefulness of urine UGP and serum CA 125 measured for gynecological neoplasias (149 cases) was evaluated using a control group of patients with benign gynecological diseases (69 cases) and healthy females (99 cases). considering the neoplastic patients in comparison to patients with benign diseases, the best diagnostic efficiency of (78%) was found to correspond to a cut=off level of 120 pmol/mol creatinine the sensitivity being 73% and the specificity 90%. With this cut-off, an efficiency of 82% for healthy controls was obtained. Since the menopausal condition increases UGP levels, and though no significant difference for UGP was found between health subjects and patients with benign diseases, we decided to consider the reference populations as a single group. Thus, we evaluated the UGP performance on the basis of menopausal status. When a specificity of 95% was fixed, the cut-off values were 120 and 180 pmol/mol creatinine for pre- and postmenopausal women respectively, the sensitivity being 73% and 64%. Finally the combined evaluation of UGP and CA 125 improved the individual clinical efficiency for the diagnosis of ovarian serous cystadenocarcinomas, assuring a sensitivity of 86% and specificity of 89%.

Original languageEnglish
Pages (from-to)3833-3838
Number of pages6
JournalAnticancer Research
Issue number6 B
Publication statusPublished - 1996


  • CA 125
  • Gynecological cancer
  • Receiver operating characteristic (ROC) curves
  • Sensitivity
  • Specificity
  • Tumor marker
  • UPG

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers'. Together they form a unique fingerprint.

Cite this